Summit Therapeutics (SMMT) is back in focus after reporting positive overall survival data from its Phase III HARMONi-6 trial in advanced squamous NSCLC, along with strong response rates in a Phase II metastatic colorectal cancer study.

Those new ivonescimab data arrive after a steady run in the stock, with a 90 day share price return of 16.08% and a very large 3 year total shareholder return, suggesting momentum has been building around Summit’s progress.

If this kind of clinical progress has your attention, it can be useful to see what else is moving in related areas, starting with 39 healthcare AI stocks

With shares up 16.08% over 90 days but still trading well below the average analyst price target, the key question now is whether Summit is still undervalued or if the stock already reflects expectations for future growth.

Most Popular Narrative: 39.9% Undervalued

Summit Therapeutics last closed at $17.54, while the most followed narrative anchors fair value closer to $29.18. This sets up a wide valuation gap driven by late stage oncology ambitions.

The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.

Want to see what kind of revenue build these trials are aiming for, and how margins and future P/E assumptions connect that story to a higher fair value? The narrative lays out a detailed path from zero revenue today to a large top line, rising profitability and a rich valuation multiple that has to hold together for the math to work.

Result: Fair Value of $29.18 (UNDERVALUED)

However, this story still hinges on a single lead asset and heavy R&D spend, so any regulatory setback or slower trial progress could quickly challenge that undervalued case.

Next Steps

If this mix of excitement and caution around Summit resonates, consider it a prompt to act quickly and evaluate the thesis using your own analysis of real numbers and scenario ranges. To weigh both sides clearly, review the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Summit has sharpened your focus, do not stop here. Broaden your watchlist now so you are not relying on a single story.

• Target potential upside by scanning companies that combine stronger fundamentals with attractive pricing using the 46 high quality undervalued stocks.
• Prioritise resilience by checking out the 64 resilient stocks with low risk scores and see which stocks carry lower risk scores while still offering meaningful exposure.
• Hunt for overlooked opportunities through the screener containing 22 high quality undiscovered gems and spot quality businesses that many investors might not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.